JORGE E CORTES to Oxides
This is a "connection" page, showing publications JORGE E CORTES has written about Oxides.
Connection Strength
0.656
-
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer. 2003 May 01; 97(9):2218-24.
Score: 0.205
-
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov; 171(4):471-7.
Score: 0.120
-
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011 Jan 01; 117(1):110-5.
Score: 0.085
-
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007 Apr 01; 109(7):1355-9.
Score: 0.067
-
Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):619-39, ix.
Score: 0.055
-
New agents in chronic myelogenous leukemia. J Natl Compr Canc Netw. 2003 Oct; 1(4):501-12.
Score: 0.053
-
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
Score: 0.028
-
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012 Dec 01; 118(23):5811-8.
Score: 0.024
-
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10.
Score: 0.019